Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €439.88 EUR
Change Today -0.133 / -0.03%
Volume 33.0
RGO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:31 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (RGO) Snapshot

Open
€437.71
Previous Close
€440.01
Day High
€447.00
Day Low
€437.71
52 Week High
08/6/15 - €553.00
52 Week Low
10/15/14 - €248.70
Market Cap
45.8B
Average Volume 10 Days
414.3
EPS TTM
--
Shares Outstanding
101.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (RGO)

regeneron pharmaceuticals (RGO) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company’s trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi to discover, develop, and commercialize human monoclonal antibodies and antibody cancer treatments; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

3,320 Employees
Last Reported Date: 08/4/15
Founded in 1988

regeneron pharmaceuticals (RGO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.2M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $905.0K
Chief Scientific Officer, Director, Member of...
Total Annual Compensation: $2.7M
Executive Vice President of Research and Deve...
Total Annual Compensation: $1.0M
Senior Vice President of Commercial
Total Annual Compensation: $843.1K
Compensation as of Fiscal Year 2014.

regeneron pharmaceuticals (RGO) Key Developments

Regeneron Pharmaceuticals, Inc. and Sanofi Announces New Positive Praluent Phase 3 Data Presented at ESC Congress 2015

Regeneron Pharmaceuticals, Inc. and Sanofi announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients included in the ODYSSEY clinical trial program, Praluent (alirocumab) significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C).1 This analysis included 1,257 HeFH patients, the group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56% greater reduction in LDL-C compared to placebo (p less than 0.0001) in both arms.1 Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.1.

Regeneron Pharmaceuticals, Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 06:15 PM

Regeneron Pharmaceuticals, Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 06:15 PM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: George D. Yancopoulos, Chief Scientific Officer, Director, Member of Technology Committee and President of Regeneron Research Laboratories.

Merus Prevails in Inequitable Conduct Case against Regeneron

Merus announced that it won its inequitable conduct trial against Regeneron. In a decision issued on August 6, Judge Katherine B. Forrest of the U.S. District Court for the Southern District of New York indicated that Regeneron engaged in inequitable conduct in connection with obtaining U.S. Patent No. 8,502,018. This marks the third counterclaim upon which Merus has prevailed in this litigation, initiated by Regeneron. In December 2014, Regeneron conceded that Merus does not infringe any claim of the ‘018 patent, and that the patent is invalid in view of the Court’s prior decision on claim construction. Given the Court’s ruling on August 6, Regeneron’s patent has now been adjudged to be not infringed, invalid and unenforceable for being procured by inequitable conduct. In that decision, the Court noted that Regeneron’s agents had withheld material information from the United States Patent Office (USPTO) during prosecution of the ‘018 patent. The Court further concluded that an adverse inference that Regeneron’s employees intentionally mislead the U.S. Patent Office was appropriate and “that Regeneron engaged in inequitable conduct in connection with the prosecution of the ‘018 patent.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €439.88 EUR -0.133

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $124.63 USD -4.61
Incyte Corp $115.12 USD -1.07
Kyowa Hakko Kirin Co Ltd ¥1,989 JPY +53.00
UCB SA €69.11 EUR +2.48
Vertex Pharmaceuticals Inc $124.04 USD -3.48
View Industry Companies
 

Industry Analysis

RGO

Industry Average

Valuation RGO Industry Range
Price/Earnings 100.0x
Price/Sales 16.3x
Price/Book 16.5x
Price/Cash Flow 122.6x
TEV/Sales 16.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.